Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Sanofi : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi Therapeutic

share with twitter share with LinkedIn share with facebook
share via e-mail
09/20/2017 | 02:57pm CET
   By Sonia Amaral Rohter 

Sanofi SA (>> Sanofi) and Alnylam Pharmaceuticals Inc. (>> Alnylam Pharmaceuticals, Inc.) reported Wednesday that Patisiran met all primary and secondary endpoints in a Phase III trial of its use against a rare, inherited disorder.

The trial looked at the use of Patisiran in patients with hereditary transthyretin-mediated amyloidosis, a progressively debilitating disease in which a gene mutation causes the production of a type of abnormal protein that accumulates in body organs and tissues, damaging them. Patisiran is designed to target and silence the mechanism that leads to production of this protein.

Patisiran is part of a class of medicines called RNA interference, or RNAi, therapeutics that aim to inhibit the expression of certain genes in order to treat or prevent disease.

Alnylam Chief Executive John Maraganore said: "We are very proud to report the first-ever positive Phase III results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines."

Alnylam said it would file a new drug application with the U.S. Food and Drug Administration in late 2017. Should the company receive regulatory approval, Alnylam will commercialize Patisiran in the U.S., Canada and Western Europe, while Sanofi Genzyme will commercialize the product in the rest of the world.

The full results of the trial will be presented on November 2.

Write to Sonia Amaral Rohter at [email protected]

Stocks mentioned in the article : Sanofi, Alnylam Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
05:41pSANOFI : Disclosure of trading in own shares
12:40pStronger European Earnings Augur More M&A, Higher Dividends
02/17SANOFI : The USB mystery
02/17SANOFI : CRN Greater Manchester Named Sanofi UK Premier Site
02/16MYOKARDIA : Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilat..
02/15Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial R..
02/15NEW VACCINES STUDY FINDINGS RECENTLY : An efficient method for antigenicity meas..
02/15SANOFI : Correction to Sanofi Dengue Vaccine Article on Feb. 2
02/15SANOFI : launches new insulin ToujeoTM in India
02/15Oxford BioMedica wins second $100 million gene therapy contract
More news
News from SeekingAlpha
08:00aYOUR DAILY PHARMA SCOOP : AbbVie's Upadacitinib, Johnson & Johnson's Tremfya, Ce.. 
02/16Sanofi (SNY) Presents At Leerink Partners 7th Annual Global Healthcare Confer.. 
02/16ROTY EDITION 1 VOLUME 80 : Adding To Select Positions And Continuing To Manage R.. 
02/16Sanofi licenses two additional Nanobody candidates from Ablynx 
02/16WALL STREET BREAKFAST : Major Recovery For Wall Street 
Financials (€)
Sales 2018 35 349 M
EBIT 2018 8 930 M
Net income 2018 5 394 M
Debt 2018 10 440 M
Yield 2018 4,74%
P/E ratio 2018 14,82
P/E ratio 2019 13,45
EV / Sales 2018 2,60x
EV / Sales 2019 2,45x
Capitalization 81 472 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 83,1 €
Spread / Average Target 29%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.62%100 587
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572